Media & Press

  • Clinical Trial for Jellyfish Sting Antidote

    Phebra is supporting a new clinical trial to test the efficacy of Magnesium Sulphate as an antidote for Irukandji Syndrome (IS), the acute pain caused by certain jellyfish stings.

    January 2015

  • Phebra Launches New Pain Relief Spray

    Phebra has launched a new pain relief spray, Kriogese® (ethyl chloride), into the Australian market.

    May 2014

  • Manufacturing and Product Supply Underway at New Phebra Plant

    Phebra’s manufacturing and product supply from its new sterile manufacturing plant is underway.

    February 2014

  • Australian Distribution of Syntometrine

    Phebra announces an agreement with Alliance Pharma to supply Syntometrine to the Australian market.

    September 2013

  • Phebra’s New Energy Efficiency Program

    Phebra is ‘going green’ and implementing an energy efficiency program at the new manufacturing plant. 

    June 2013

  • New Phebra Plant receives TGA manufacturing licence

    Phebra welcomes the granting of its licence from the TGA for its new sterile manufacturing plant

    May 2013

  • Industry and Innovation Minister Greg Combet Opens New Phebra Pharmaceutical Plant

    Federal Minister for Industry and Innovation, Greg Combet, officially opened and inspected Phebra’s new sterile manufacturing plant.

    March 2013

  • Phebra commences validation manufacturing at new plant

    The first stage of validation manufacturing at Phebra’s new plant begins

    December 2012

  • Phebra welcomes PBS listing of Naproxen

    Naproxen suspension is approved for reinbursement through the Pharmaceutical Benefits Scheme (PBS)

    November 2012

  • TGA approval of Phebra’s Naproxen oral suspension

    The Australian pharmaceutical company Phebra, announced today that the Therapeutic Goods Administration (TGA) has granted Phebra marketing approval for Naproxen oral suspension, an alternative to the previously available Naprosyn® oral suspension.

    October 2012